Today: 9 April 2026
Subscribe
Browse Category

NSE:AEQUS 10 December 2025

Indian Stock Market Today, 10 December 2025: Sensex, Nifty Extend Losing Streak Ahead of Fed; Meesho Soars Over 50% on Debut

Indian Stock Market Today, 10 December 2025: Sensex, Nifty Extend Losing Streak Ahead of Fed; Meesho Soars Over 50% on Debut

The Sensex fell 275 points to 84,391.27 and the Nifty 50 dropped 81.65 points to 25,758 on Wednesday, marking a third straight decline. Broader markets underperformed, with midcaps and smallcaps posting steeper losses. Foreign investors sold ₹1,651 crore in equities, while domestic funds bought ₹3,752 crore. The rupee closed at 89.97 per US dollar, near record lows.
10 December 2025
··
Aequs Ltd (AEQUS) IPO Listing 10 December 2025: 13% Premium Debut, Share Price Today, Broker Views and Outlook

Aequs Ltd (AEQUS) IPO Listing 10 December 2025: 13% Premium Debut, Share Price Today, Broker Views and Outlook

Aequs Ltd shares debuted at ₹140 on NSE and BSE Wednesday, 12.9% above the ₹124 IPO price, valuing the company at about ₹9,500 crore. By early afternoon, the stock traded near ₹142.3, up nearly 15% from issue price, with over 75 lakh shares and ₹100 crore turnover on BSE. Intraday prices ranged from ₹135.4 to ₹151 amid volatile trade. The listing fell short of grey-market expectations of a ₹155 debut.
10 December 2025
··
Aequs IPO Listing Today: Share Price Jumps 13% on Debut – Allotment Status, GMP, Subscription and Business Model Explained

Aequs IPO Listing Today: Share Price Jumps 13% on Debut – Allotment Status, GMP, Subscription and Business Model Explained

Aequs Limited shares listed at ₹140 on NSE and BSE, a 12.9% premium over the ₹124 IPO price, on December 10. The ₹921.81 crore IPO was subscribed 101.63 times, with strong demand from institutional and retail investors. A retail allotment of 120 shares saw a notional gain of about ₹1,920 per lot at listing. Book-running lead managers included JM Financial, IIFL Capital, and Kotak Mahindra.
10 December 2025
···

Stock Market Today

  • AbbVie's Humira Launch on TrumpRx with 86% Discount Sparks Valuation Questions
    April 9, 2026, 9:02 AM EDT. AbbVie (NYSE:ABBV) has introduced Humira on the TrumpRx platform at an 86% discount under a White House pricing deal aiming to reduce patient costs and widen drug access. This marks a significant US pricing strategy shift post exclusivity for Humira, a key immunology therapy driving substantial revenue. The stock trades near $206.69, about 20% below analyst targets and 43.8% under fair value estimates. The deep discount could alter patient volume, payer ties, and pricing benchmarks in government-linked drug programs. AbbVie's revenue exposure of $61.2 billion and a high price-to-earnings ratio of 87.3 place focus on potential impacts to cash flow and dividends amid its debt load. Investors should monitor reactions from payers, competitors, and capital markets to this pricing shift that could redefine AbbVie's US market dynamics.

Latest article

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

9 April 2026
Brent crude rebounded 3% Thursday despite a U.S.-Iran ceasefire, with the Strait of Hormuz still nearly shut and only one oil-products tanker passing in 24 hours. U.S. gasoline averaged $4.166 a gallon on April 9, and AAA said prices could drop slowly. North Sea Forties crude hit a record $146.43 a barrel. The U.S. EIA expects Hormuz flows may take months to recover.
CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

9 April 2026
CoreWeave said Meta Platforms committed about $21 billion for AI cloud capacity through December 2032. Shares rose 4.3% to $88.90 in premarket trading after the announcement. The deal follows an $8.5 billion loan facility and a $1.25 billion senior notes offering. CoreWeave reported $5.13 billion in 2025 revenue and ended December with a $66.8 billion backlog.
NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

9 April 2026
TrendForce said April 8 that Nvidia’s Rubin AI chip shipments may be delayed by HBM4 memory qualification and cooling demands, shifting over 70% of 2026 high-end GPU volume to the current Blackwell line. Rubin’s projected share dropped to 22%. Samsung began shipping HBM4 to Nvidia in February, but SK Hynix and Micron face qualification delays. Broadcom signed a long-term deal to develop Google’s TPUs through 2031.
Go toTop